Abstract
Hyperuricemia (HUA) is a chronic condition characterized by abnormal purine metabolism. SHECN (Ser-His-Glus-Cys-Asn), a soy-derived peptide, has demonstrated uric acid (UA) lowering and antioxidant properties in vitro. The aim of this study was to further explore its uric acid lowering potential in hyperuricemia mice. The results indicated that UA level in SHECN-H group (40 mg/kg) was reduced to 32.80 ± 1.23 μmol/L compared with that in HUA group (104.46 ± 7.30 μmol/L). SHECN group decreased serum xanthine oxidase (XO) and adenosine deaminase (ADA) activities, AST and ALT activities. Additionally, SHECN significantly ameliorated fiber damage observed in mouse liver tissue. We also found that under the action of SHECN, the active expression of XO and ADA in serum and liver was down-regulated, and the expression of hypoxanthine-guanine phosphoribosyl transferase (HGPRT) was up-regulated. Notably, SHECN effectively mimics interactions with XO-associated target proteins as well as key liver transporter receptor proteins. This study further confirmed that SHECN can affect the activity level of the key receptor protein of uric acid synthesis in the liver of mice, and ultimately reduce the serum uric acid level and alleviate liver injury (P < 0.05).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
